Global Information
회사소개 | 문의

녹내장 치료제 리포트(2017년) : 세계 시장 분석(2016-2022년)

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022

리서치사 Market Scope, LLC
발행일 2017년 12월 상품 코드 644810
페이지 정보 영문
가격
US $ 6,500 ₩ 7,399,600 Hard Copy
US $ 7,000 ₩ 7,968,800 Hard Copy & PDF by E-mail (Single User License)
US $ 9,750 ₩ 11,099,400 Hard Copy and PDF by E-mail (Enterprise License)


녹내장 치료제 리포트(2017년) : 세계 시장 분석(2016-2022년) 2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022
발행일: 2017년 12월 페이지 정보 : 영문

한글목차

녹내장 치료제 시장 규모는 2022년에 53억 달러에 이를 것으로 예측됩니다.

세계의 녹내장 치료제(Glaucoma Pharmaceuticals) 시장에 대해 조사했으며, 녹내장 개요, 유병률과 진단 사례, 의료기관, 진단법, 치료법, 시판약, 처방약의 개발 파이프라인, 외과수술에서 사용되는 보조약 및 주요 기업 개요 등의 정보를 전해드립니다.

1. 서론

2. 주요 요약

3. 녹내장에 대해

  • 개방각 녹내장(OAG)
  • 폐쇄각 녹내장(ACG)
  • 원발성 녹내장의 위험인자
  • 이차성 녹내장
  • 색소성 녹내장
  • 신생혈관 녹내장
  • 포도막염 녹내장
  • 외상성 녹내장
  • 스테로이드 녹내장
  • 수정체 녹내장
  • 홍채각막내피 증후군(ICE 증후군)
  • 선천성 녹내장
  • 고안압증(OHT)
  • 녹내장의 유전적 특징

4. 녹내장의 유병률

  • 녹내장의 유병률 조사 개요
  • 세계의 유병률 : 질환 종류별
  • 세계의 녹내장 분포를 형성하는 요인
  • 녹내장
  • POAG의 진단
  • PACG의 진단
  • 미국
  • 서유럽
  • 일본
  • 기타 부유국
  • 중국
  • 인도
  • 라틴아메리카
  • 기타(ROW)
  • 녹내장 인구의 증가

5. 녹내장의 의료기관

  • 의료기관, 진단, 치료 개요
  • 의료기관 및 진단시설
  • 미국의 의료기관
  • 서유럽의 의료기관
  • 일본의 의료기관 등

6. 녹내장의 진단

  • 안압측정
  • 각막두깨측정
  • 시야 검사 및 시력 검사
  • 검안경 검사
  • 안저 촬영
  • 광간섭단층촬영(OCT)
  • 공초점 주사형 레이저 검안경(SLO) 등

7. 녹내장의 치료

  • 치료법
  • 처방약
  • 개방각 녹내장(OAG) 치료
  • 고안압 환자의 IOP 치료
  • 박리/거짓비늘(Pseudoexfoliation) 치료
  • 녹내장(XFG/PEG)
  • 폐쇄각 녹내장(ACG) 치료
  • 현재 치료제의 한계
  • 녹내장 전문의에 대한 소개
  • 레이저와 외과수술 등

8. 녹내장 관리의 과제

  • IOP의 주요 역할
  • IOP 및 녹내장에 관한 경쟁 이론
  • 녹내장 치료 선택사항의 증가
  • 안과의가 최선의 POAG 치료 선택사항을 결정하는 방법
  • POAG 병기 및 전형적인 치료 방법

9. 시장의 녹내장 치료제

  • Rho 키나아제 억제제
  • 프로스타글란딘 유사체 및 프로스타마이드
  • 합성 도코사노이드
  • 베타 차단제
  • 알파 작용제
  • 탄산탈수효소 억제제
  • 콜린 작용제 등

10. 녹내장 치료제 시장 예측

  • 부유국의 전망
  • 신흥 시장의 경제 전환
  • 녹내장 수술의 역할 변화
  • 세계의 녹내장 치료제 시장
  • 세계 시장 : 치료제 클래스별
  • 세계 시장 : 경쟁사별
  • 세계의 녹내장 처방약 시장 예측 등

11. 녹내장 치료제 개발 파이프라인

  • 프로스타글란딘 유사체
  • Rho 키나아제 억제제
  • 아데노신 수용체 작용제 및 길항제
  • EP 수용체 작용제
  • 신경세포보호 및 신경재생 등

12. 녹내장 외과수술에 사용되는 보조약

  • 오프라벨로 사용되는 화합물
  • Mobius Therapeutics Mitosol
  • Altacor/Esperante ALT 401(Tranilast)

13. 기업 개요

  • Aerie Pharmaceuticals
  • Akorn
  • Allergan, PLC
  • Amorphex Therapeutics LLC
  • Bausch + Lomb
  • Envisia Therapeutics
  • Inotek Pharmaceuticals Corporation
  • Laboratoires Théa
  • Laboratorios Sophia, SA de CV
  • MatiTherapeutics, Inc.
  • Merz GmbH & Co. KGaA
  • Mobius Therapeutics LLC
  • Neurotech Pharmaceuticals, Inc.
  • Nicox
  • Novartis
  • Ocular Therapeutix
  • Ono Pharmaceutical Co., Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfi zer
  • pH Pharma
  • Quark Pharmaceuticals
  • Santen Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries, Inc.
  • Sylentis
  • Teva
  • ViSci Ltd.
KSM 18.06.11

영문목차

Our 2017 report on the glaucoma pharmaceutical market is the only glaucoma market report to include a detailed analysis of prevalence of types of glaucoma, glaucoma providers, treatments, and compliance, as well as unit breakdown by drug class.

What's New?

The outlook for the glaucoma pharmaceuticals market is growing more positive as new products with new mechanisms of action begin commercialization or enter the final stages of the regulatory approval process. Market Scope estimates the glaucoma pharmaceuticals market will reach $5.3 billion in 2022. However, prospects vary considerably by region.

Our report on the glaucoma pharmaceuticals market, now in its fourth edition, is a leading industry source for accurate and relevant information on all aspects of the glaucoma pharmaceuticals market. The glaucoma pharmaceuticals market is one of the largest and most complex market segments in ophthalmology with a variety of drug classes, as well as proprietary and generic versions of many drugs. Current ocular hypotensive medication classes used to treat glaucoma were developed 20 years ago or more, and generic versions of these medications are now in widespread use.

We analyze worldwide markets using the following geographic/economic categories: the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World. This report includes market data for 2016, and we forecast market performance through 2022.

ABOUT THE AUTHOR

Peter Downs

Peter Downs has more than 30 years of experience as a business and medical journalist and investigative reporter. He has written for a variety of medical industry publications, including the Medical Business Journal, CBS HealthWatch, and Oncology News International.

Prior to joining Market Scope in 2015 and turning his attention to ophthalmology, Peter analyzed markets for organ and tissue transplantation. Since joining Market Scope, he has traveled to several markets outside the US, including China and India, to study ophthalmology at the local level.

In addition to his research and writing efforts on the ophthalmic market, he is also a contributor to Ophthalmic Market Perspectives, the firm's monthly industry.

Four Disease Categories Are Analyzed In This Report:

Primary Open-angle Glaucoma (POAG), Primary Angle-closure Glaucoma (PACG), Other Secondary OAG and ACG, and Ocular Hypertension (OHT)

Each Market Segment Includes:

An Analysis of Market Competitors and Five-Year Forecasts for Market Performance

Also Included in This Report:

  • Overview of Glaucoma
  • Prevalence of Glaucoma and Diagnosed Cases
  • Glaucoma Care Providers
  • Diagnosing Glaucoma
  • Treating Glaucoma
  • Glaucoma Medications in the Marketplace
  • Development Pipeline for Glaucoma Rx
  • Adjunctive Drugs Used in Glaucoma Surgery
  • 26 Company Profiles
  • 54 Color Tables and 36 Color Figures

This edition of our ‘2017 Glaucoma Pharmaceutical Report ’is scheduled to release in August 2017. The report is printed in color and spiral bound for easy reading.

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective ophthalmic experience and each data point is driven by a combination of sources, including the following:

  • Our proprietary global disease population and demographic models
  • Twenty years and counting of ophthalmologist survey data
  • Analysis of company published financial reports
  • Focused coverage of ophthalmic scientific research, business news and other activities
  • Attendance and participation in major, worldwide ophthalmic meetings
  • Interviews and long-standing relationships with company executives and practicing ophthalmologists

Table of Contents

INTRODUCTION

  • Scope of Report
  • Methodology
  • About the Author
  • The Report at a Glance

EXECUTIVE SUMMARY

  • Glaucoma and its Prevalence
  • The Global Market
  • Current Market Competitors
  • Factors Shaping the Marketplace

ABOUT GLAUCOMA

  • Open-Angle Glaucoma (OAG)
  • Normal-Tension Glaucoma as a Subset of OAG
  • Exfoliation Glaucoma (XFG) as a Subset of OAG
  • Angle-Closure Glaucoma (ACG)
  • Risk Factors for Primary Glaucomas
  • Secondary Glaucomas
  • Pigmentary Glaucoma
  • Neovascular Glaucoma
  • Uveitic Glaucoma
  • Trauma-Related Glaucoma
  • Steroid-Induced Glaucoma
  • Lens-Induced Glaucoma
  • Iridocorneal Endothelial Syndrome
  • Congenital Glaucoma
  • Ocular Hypertension (OHT)
  • Genetics of Glaucoma

PREVALENCE OF GLAUCOMA

  • Overview of Glaucoma Prevalence Research
  • Global Prevalence by Disease Type
  • Factors Shaping Worldwide Distribution of
  • Glaucoma
  • Diagnosed POAG
  • Diagnosed PACG
  • United States
  • Western Europe
  • Japan
  • Other Wealthy Nations
  • China
  • India
  • Latin America
  • Rest of World
  • Growth in Glaucoma Populations

GLAUCOMA CARE PROVIDERS

  • Overview of Providers, Diagnosis, Treatment
  • Care Providers and Diagnostic Facilities
  • US Providers
  • US Ophthalmologists and Glaucoma Specialists
  • Profi le of the US Ophthalmologist
  • Profi le of the US Optometrist
  • Western Europe's Providers
  • Ophthalmology and Health Care Systems
  • Optometry
  • Japan's Providers
  • Ophthalmology and the Health Care System
  • Optometry
  • Other Wealthy Nations' Providers
  • Ophthalmology and Health Care Systems
  • Optometry
  • China's Providers
  • Ophthalmology and the Health Care System
  • Optometry
  • India's Providers
  • Ophthalmology and the Health Care System
  • Optometry
  • Latin America's Providers
  • Ophthalmology and Health Care Systems
  • Optometry
  • Select Country Snapshots
  • Rest of World's Providers
  • Ophthalmologist and Health Care Systems
  • Optometry
  • Glaucoma Organizations and Foundations

DIAGNOSING GLAUCOMA

  • Tonometry
  • Pachymetry
  • Perimetry or Visual Field Testing
  • Ophthalmoscopy
  • Fundus Photography
  • Optical Coherence Tomography
  • Confocal Scanning Laser Ophthalmoscopy
  • Scanning Laser Polarimetry
  • Glaucoma Scope Examination
  • Slit Lamp Biomicroscopy
  • Gonioscopy with Contact Lens
  • Ultrasound Biomicroscopy
  • Diagnosed Disease Rates
  • Growth in Glaucoma's Diagnosis

TREATING GLAUCOMA

  • Treatment Modalities
  • Rx Medications
  • Treating Open-Angle Glaucoma
  • Treating IOP in Ocular Hypertension Patients
  • Treating Exfoliation/Pseudoexfoliation
  • Glaucoma (XFG/PEG)
  • Treating Angle-Closure Glaucoma
  • Limitations of Current Medications
  • Referral to Glaucoma Specialists
  • Laser and Surgery
  • Laser Procedures
  • Traditional Surgical Treatment
  • Newer Surgical Approaches
  • Traditional Medicine and Alternative Therapies
  • China
  • India
  • Other Alternative Medicine
  • Marijuana

THE CHALLENGES OF MANAGING GLAUCOMA

  • The Key Role of IOP
  • A Competing Theory Regarding IOP and
  • Glaucoma
  • Growing Glaucoma Treatment Options
  • How Ophthalmologists Determine the Best
  • POAG Treatment Option
  • POAG Stages and Typical Treatment Approaches

GLAUCOMA MEDICATIONS IN THE MARKETPLACE

  • Rho Kinase Inhibitor
  • Prostaglandin Analogs and Prostamides
  • Synthetic Docosanoids
  • Beta Blockers
  • Alpha Agonists
  • Selective Alpha Adrenergic Agonists
  • Nonselective Alpha Adrenergic Agonists
  • Carbonic Anhydrase Inhibitors
  • Cholinergic Agonists
  • Fixed Combination Medications
  • Comparative IOP Reduction: Brands and MOAs
  • The Market Mix: Original Medications and
  • Generics
  • Branded Proprietary IOP-lowering Medications
  • Generic IOP-lowering Medications
  • Branded Generics

FORECAST FOR THE GLAUCOMA PHARMA MARKET

  • Prospects in Wealthy Nations
  • Economic Shifts in Emerging Markets
  • Changing Role of Glaucoma Procedures
  • Global Market for Glaucoma Medications
  • The Global Market by Medication Class
  • The Global Market by Competitor
  • Forecast for the Global Glaucoma Rx Market
  • US Market for Glaucoma Medications
  • Western Europe's Market for Glaucoma
  • Medications
  • Japan's Market for Glaucoma Medications
  • OWN's Market for Glaucoma Medications
  • China's Market for Glaucoma Medications
  • India's Market for Glaucoma Medications
  • Latin America's Market for Glaucoma
  • Medications
  • ROW's Market for Glaucoma Medications

DEVELOPMENT PIPELINE FOR GLAUCOMA PHARMA

  • Prostaglandin Analogs
  • Bausch + Lomb/Nicox: Vyzulta
  • Nicox: NCX 470
  • Ono Pharmaceutical/Santen Sepetaprost
  • Santen/Novagali Pharma: Catioprost
  • Rho-kinase Inhibition
  • Aerie Pharmaceuticals: Rhopressa
  • pH Pharma PHP-201
  • Discontinued Rho-Kinase Inhibitors
  • Adenosine Receptor Agonists and Antagonists
  • Inotek Pharmaceuticals: Trabodenoson
  • Acorn Biomedical: ACN-1052
  • Discontinued Adenosine Receptor Agonists
  • EP Receptor Agonists
  • Santen: DE-117 (omidenepag isopropyl)
  • Discontinued EP Receptor Agonists
  • Additional IOP-lowering Compounds
  • Sylentis: Bamosiran (SYL-040012)
  • Neuroprotection and Neuroregeneration
  • Quark Pharmaceuticals: QPI-1007
  • Merz Pharmaceuticals: MRZ-99030
  • Other Neuroprotective Compounds
  • Discontinued Candidates
  • Fixed Combinations of Agents
  • Aerie Pharmaceuticals: Roclatan
  • Inotek: Trabodenoson Plus Latanoprost
  • Laboratoires Théa: T2347
  • New Drug Delivery Technologies
  • Clinical Stage Programs
  • Preclinical Programs
  • Review of Investigational Technologies

ADJUNCTIVE DRUGS USED IN GLAUCOMA SURGERY

  • Compounds Used Off Label
  • Mobius Therapeutics' Mitosol
  • Altacor/Esperante's ALT 401 (Tranilast)

COMPANY PROFILES

  • Aerie Pharmaceuticals
  • Akorn
  • Allergan, PLC
  • Amorphex Therapeutics LLC
  • Bausch + Lomb
  • Envisia Therapeutics
  • Inotek Pharmaceuticals Corporation
  • Laboratoires Théa
  • Laboratorios Sophia, SA de CV
  • MatiTherapeutics, Inc.
  • Merz GmbH & Co. KGaA
  • Mobius Therapeutics LLC
  • Neurotech Pharmaceuticals, Inc.
  • Nicox
  • Novartis
  • Ocular Therapeutix
  • Ono Pharmaceutical Co., Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfi zer
  • pH Pharma
  • Quark Pharmaceuticals
  • Santen Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries, Inc.
  • Sylentis
  • Teva
  • ViSci Ltd.
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
La Merie Publishing
BCC Research